Using Patient-Derived Laboratory Models of Childhood Cancers to Identify Cancer Vulnerabilities Exploitable for Therapy

Dr. Reynolds is the Cancer Center Director for the School of Medicine, Texas Tech University Health Sciences Center (http://cancer.ttuhsc.edu). His research focuses cancer developmental therapeutics and he pioneered the development of the differentiating agent isotretinoin for treating the childhood cancer neuroblastoma. Other research interests include mechanisms of resistance to drugs and antibody therapy in childhood and adult cancers, biobanking of human cancers, and development of novel preclinical testing systems for cancer drug development. His most recent research focuses on use of telomere maintenance mechanisms as prognostic markers and developing agents to specifically target alternate telomere lengthening (ALT) cancers. He has sponsored multiple investigational New Drug (IND) applications with the FDA and receives grant funding from the NIH, DOD, ALSF, and CPRIT.